Apexigen, Inc. financial data

Industry
Pharmaceutical Preparations
Location
900 Industrial Road, Suite C, San Carlos, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Brookline Capital Acquisition Corp. (to 8/1/2022)
Latest financial report
10-Q - Q2 2023 - Aug 10, 2023

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 119 % -24.7%
Debt-to-equity 361 % +933%
Return On Equity -615 % -139%
Return On Assets -133 % -51.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 24.9M shares +269%
Common Stock, Shares, Outstanding 24.9M shares +1375%
Entity Public Float 204M USD +242%
Common Stock, Value, Issued 2K USD +1090%
Weighted Average Number of Shares Outstanding, Basic 24.7M shares +36.7%
Weighted Average Number of Shares Outstanding, Diluted 24.7M shares +36.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 14.6M USD -70.8%
General and Administrative Expense 13.2M USD +17.7%
Operating Income (Loss) -27.8M USD +39.4%
Income Tax Expense (Benefit) 2.3M USD +10852%
Net Income (Loss) Attributable to Parent -27M USD +40.8%
Earnings Per Share, Basic -1.16 USD/shares +46.7%
Earnings Per Share, Diluted -1.16 USD/shares +46.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 9.37M USD
Cash, Cash Equivalents, and Short-term Investments 9.4M USD
Assets, Current 12.6M USD +10398%
Property, Plant and Equipment, Net 0 USD
Operating Lease, Right-of-Use Asset 0 USD
Other Assets, Noncurrent 335K USD
Assets 13.1M USD -74.8%
Accounts Payable, Current 3.38M USD +2442%
Employee-related Liabilities, Current 601K USD
Accrued Liabilities, Current 5.36M USD +48.9%
Contract with Customer, Liability, Current 6.66M USD
Liabilities, Current 15.4M USD +220%
Operating Lease, Liability, Noncurrent 0 USD
Liabilities 15.4M USD +219%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -189M USD -3982%
Stockholders' Equity Attributable to Parent -2.32M USD -141%
Liabilities and Equity 13.1M USD -74.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.76M USD +18.9%
Net Cash Provided by (Used in) Financing Activities 2.54M USD
Net Cash Provided by (Used in) Investing Activities 2.15M USD -14.7%
Common Stock, Shares Authorized 1B shares +3900%
Common Stock, Shares, Issued 24.9M shares +1375%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.07M USD +64.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9.37M USD -19.5%
Deferred Tax Assets, Valuation Allowance 44.5M USD +37.4%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure
Cash and Cash Equivalents, Period Increase (Decrease) -124K USD -130%
Deferred Tax Assets, Gross 44.5M USD +36.9%
Operating Lease, Liability 0 USD
Depreciation 17K USD -39.3%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -27M USD +25.5%
Lessee, Operating Lease, Liability, to be Paid 106K USD
Property, Plant and Equipment, Gross 0 USD
Operating Lease, Liability, Current 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year One 106K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD
Deferred Tax Assets, Operating Loss Carryforwards 33.3M USD +22.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 20M shares +1900%
Unrecognized Tax Benefits 2M USD +25.3%
Additional Paid in Capital 187M USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 71K USD -100%
Share-based Payment Arrangement, Expense 1.93M USD -4.08%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%